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Summary 
Inoculation of plasmid vectors encoding a viral protein 
into muscle tissue was shown to result in expression 
of the transantigen and, consequently, an antiviral im- 
mune response. Here, we show that coinoculation of 
a plasmid expressing the glycoprotein of rabies virus 
with plasmids encoding mouse cytokines modulated 
the immune response to the viral protein. Coinocula- 
tion with a vector expressing mouse granulocyte-mac- 
rophage colony-stimulating factor (GM-CSF) enhanced 
the B and T helper cell activity to rabies virus, while 
coinoculation with a plasmid expressing interferon-y 
(IFNy) resulted in a decrease of the immune response 
to the viral antigen. 
Introduction 
A novel approach for induction of primary immune re- 
sponses based on plasmid vectors carrying microbial 
genes has been developed recently. Intramuscular inocu- 
lation of experimental animals with such plasmid vectors 
was shown to result in vector-derived expression of anti- 
gens in striated muscle cells (Wolff et al., 1990) and, con- 
sequently, in an antiviral immune response (Ulmer et al., 
1993; Wang et al., 1993; Xiang et al., 1994) providing pro- 
tection against viral challenge. Vector vaccines referred 
to as"naked" DNA vaccines (Cohen, 1993) have numerous 
potential advantages over traditional vaccines: similar to 
infectious vaccines such as attenuated viruses or viral re- 
combinants, plasmid vectors lead to the activation of CD8 + 
cytolytic T cells (Wang et al., 1993, Xiang et al., 1994) that 
play a major role in limiting the spread of numerous viruses 
(Yap et al., 1978). Infectious vaccines induce long-lasting 
protective immunity, which presumably reflects the anti- 
genic load produced by replicating agents; plasmid vec- 
tors also stimulate a prolonged immune response (Yan- 
kaukas et al., 1993, Davis et al., 1993, Donnelly et al., 
1994), which might be caused by antigenic persistence 
(Wolff et. al., 1992). Replicating vaccines are commonly 
burdened with side effects, owing to their infectious na- 
ture. Although safety issues need to be addressed more 
carefully for DNA vaccines, results thus far indicate that 
the plasmid DNA persists episomally without replication 
or incorporation into the host cell genome (Wolff et al., 
1990, 1992). Serious inflammatory reactions at the site of 
inoculation or other complications have not been observed 
thus far. 
Numerous questions remain to be addressed with re- 
gard tothe basic mechanisms that are involved in inducing 
an immune response upon inoculation of vector DNA. The 
role of the mode of inoculation that might affect the trans- 
fection rate and certain characteristics of the vector, such 
as size or regulatory element, which might affect the tran- 
scription rate, should be investigated (Davis et al., 1993; 
Montgomery et al., 1994). Furthermore, the pathway of 
processing and presentation of vector encoded-antigen, 
and the reason for the apparent antigenic persistence in 
spite of an ongoing immune response, remain to be eluci- 
dated. 
To address some of these questions, we tested the ef- 
fect of coinoculation of inbred mice with a rabies virus 
glycoprotein (G protein)-expressing plasmid (Burger et al., 
1991) that was shown previously to induce an antiviral 
immune response (Xiang et al., 1994) and plasmids encod- 
ing mouse cytokines. Granulocyte-macrophage colony- 
stimulating factor (GM-CSF) was used because this cyto- 
kine is known to facilitate the induction of primary immune 
responses (Tao and Levy, 1993) by activating and recruit- 
ing professional antigen-presenting cells (APCs) (Heufler 
et al., 1988; Fischer et al., 1988; Morrisey et al., 1987). 
Mouse interferon Y (IFN'y) was tested because it regulates 
immune responses by up-regulating the expression of ma- 
jor histocompatibility complex (MHC) determinants on a 
variety of cells (Steeg et al., 1982; Fabry et al., 1994), 
including myoblasts and myocytes (reviewed by Hohlfeld 
and Engel, 1994), the primary target cells for in situ DNA 
transfection (Wolff et al., 1990). 
Using the approach described in this manuscript, we 
first wanted to establish whether coinoculation of an anti- 
gen-expressing vector with a cytokine-expressing vector 
is a suitable method to manipulate the immune response 
to the vector-encoded viral antigen, as conflicting results 
using coexpression of interleukin-2 (IL-2) had indicated 
(Watanabe et al., 1993; Abai et al., 1994). Cytokines exert 
their effect locally, presumably within a few cell diameters. 
In vitro cotransfection of a low percentage of sensitive 
cells within a given culture is common. Our current studies 
tested whether this rule, which we consider a prerequisite 
for the success of the tested coimmunization approach, 
might also apply to in situ transfection. Second, we wanted 
to establish whether the efficacy of a DNA vaccine can 
be modulated by simultaneous expression of cytokines. 
Third, comparing the effects of these two cytokines, i.e., 
GM-CSF and IFNy, both of which regulate immune re- 
sponses, albeit by different pathways, was anticipated to 
give further insight into the cellular mechanisms involved 
in initiating the immune response to vector-encoded pro- 
teins. Deciphering the immunological sequences follow- 
ing direct gene transfer into striated muscle cells, a 
method that might not only resolve in novel vaccines but 
might also be suitable for gene therapy (Dai et al., 1992), 
is crucial to assessing rationally the suitability of this ap- 
proach for either purpose. 
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Table 1. The Effect of GM-CSF on the VNA Response to DNA Vaccination 
VNA Titers Percent 
Immunization First Second Third Survival 
20 tag pSG5 + 100 tag pRJB-GM 1:5 1:5 ND 0 
20 tag pSG5rab.gp + 100 tag pRJB-GM 1:25 1:405 1:3650 87 
20 tag pSG5rab.gp + 100 tag pRJB-c 1:15 1:60 1:405 87 
Groups of eight C3H/He mice were injected intramuscularly with a mixture of 20 tag of pSG5rab.gp or, as a control, 20 p_g of pSG5 and 100 tag 
of pRJB-GM or 100 tag of pRJB-c as a control (first), mice were bled 14 days later and serum antibody titers to rabies virus were determined by 
a neutralization assay. Mice were boosted 14 days after the initial inoculation with 20 tag of either pSG5rab.gp or pSG5 vector (second); they were 
bled 7 days later and serum antibody titers were determined. Mice were challenged 14 days after the second immunization with 10 LDs0 of rabies 
virus (third). Surviving mice were bled 14 days afater challenge and serum antibody titers were determined. 
ND, not done; none of the animals survived. 
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Figure 1. Effect of GM-CSF on the B Cell Response to the DNA Vaccine 
Groups of C3H/He mice were inoculated with 50 tag of pSG5rab.gp 
vector and varied doses of pRJB-GM vector. Mice were boosted 3 
weeks later with 50 tag of pSG5rab.gp vector. Mice were bled 7 days 
later and serum antibody titers were determined by an ELISA. Data 
represent the mean of duplicate wells _+ standard eviations. Closed 
triangle, 50 pg of pSG5rab.gp; open triangle, 50 pg of pSG5rab.gp 
plus 10 tag of pRJB-GM; open square, 50 tag of pSG5rab.gp lus 50 
tag of pRJB-GM; closed square, 50 ~tg of pSG5rab.gp lus 250 tag of 
pRJB-GM; x, normal mouse serum (NMS). 
Results 
A Plasmid Vector Expressing Mouse GM-CSF 
Enhances the Antibody Response to a 
Vector-Encoded Viral Protein 
Cytokines play a major role in stimulation of a primary 
immune response by providing signals between different 
cell types. GM-CSF, a cytokine secreted by multiple cells, 
including activated lymphocytes, improves the immune 
response to traditional antigens. To test for an effect of 
GM-CSF on the immune response to a DNA vaccine, 
groups of C3H/He mice were inoculated with mixtures of 
50 Ixg of a plasmid encoding the rabies virus G protein 
of the Evelyn-Rokitniki-Abelseth (ERA) strain, termed 
pSG5rab.gp (Burger et al., 1991), and varied amounts 
(10-250 ~g) of a plasmid, termed pRJB-GM (Altmann et 
al., 1991), expressing mouse GM-CSF. Mice were bled 
14 days later and antibody titers to rabies virus tested 
by an enzyme-linked immunosorbent assay (ELISA) were 
found to be only borderline positive for all of the groups. 
Mice were subsequently, i.e., 3 weeks after the initial inoc- 
ulation, boosted with 50 tag of the pSG5rab.gp vector given 
into the same muscle as the original inoculation. Antibody 
titers determined 1week later showed a marked increase 
in mice that had been primed with the rabies virus G protein 
expressing vector in presence of the plasmid encoding 
mouse GM-CSF. The increase of the response was dose 
dependent; mice that received the lowest amount of pRJB- 
GM (10 ~g) had levels of antiviral antibodies comparable 
to those in the sera of animals inoculated with the 
pSG5rab.gp vector only (Figure 1). 
The enhancing effect of the GM-CSF-expressing vector 
on the immune response to the G protein-encoding vector 
depended on coinjection of the two plasmids; inoculation 
of the two plasmids separately several hours apart had 
no effect on the magnitude of the antibody response to 
rabies virus, suggesting that either cotransfection of indi- 
vidual cells with both vectors or close proximity of APCs 
to GM-CSF-secreting cells was crucial, presumably re- 
flecting the localized activity of the cytokine (data not 
shown). 
To ensure that the increased antibody titers to rabies 
virus were indeed related to vector-driven expression of 
mouse GM-CSF, groups of C3H/He mice were inoculated 
with mixtures of the pSG5rab.gp (20 ixg/mouse) and pRJB- 
GM (100 i.tg/mouse) vectors or either of these plasmid 
vectors in combination with the appropriate mpty control 
vectors (pSG5 for pSG5rab.gp and pRJB-c for pRJB-GM). 
Mice were boosted 14 days after the initial inoculation with 
20 Ixg of either pSG5rab.gp or pSG5; they were challenged 
2 weeks after the second immunization with a mean of 10 
lethal doses (LDso) of rabies virus strain challenge virus 
standard (CVS)-24, which is antigenically closely related 
to the ERA strain but shows higher virulence in mice. Sera 
were harvested and tested for rabies virus neutralizing 
antibodies (VNA) 14 days after the initial immunization, 7
days after the booster inoculation and, in surviving mice, 
• 14 days after viral challenge. As shown in Table 1, one 
immunization with or without coinoculation of the GM-CSF 
expressing plasmid resulted in a marginal VNA response 
that upon booster immunization with the antigen-expressing 
vector was clearly superior in mice that had been primed 
with the pRJB-GM plasmid. The enhancing effect of GM- 
CSF was even more pronounced after an additional anti- 
genic stimulus in the form of live rabies virus, which, under 
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Table 2. The Effect of IFNy on the VNA Response to DNA 
Vaccination 
Immunization VNA Titers 
50 p.g pSG50rab.gp 1:145 
50 p.g pSG5rab.gp + 100 ~g pSV2muyII 1:45 
Control 1:15 
Groups of mice were inoculated with plasmid(s) in saline. Sera were 
harvested 4weeks later and tested for neutralizing antibodies to ERA 
virus. Sera from age- and sex-matched unimmunized mice were used 
as a control. 
the experimental conditions, caused a lethal infection in 
all of the control animals, while mice immunized with the 
pSG5rab.gp vector (with or without pRJB-GM) were fully 
protected. 
A Plasmid Vector Expressing Mouse GM-CSF 
Enhances the T Helper Cell Response to a 
Vector-Encoded Viral Protein 
The enhancement of the VNA response upon coimmuniza- 
tion with the GM-CSF-expressing vector might reflect a 
primary effect of this cytokine on the T helper cell re- 
sponse, which, in turn, would result in an increased activa- 
tion of antigen-specific B cells. To test this hypothesis, 
groups of C3H/He mice were injected with mixtures of 
the two expression vectors or the control constructs. Mice 
were euthanized 3 weeks after a single immunization and 
splenocytes were restimulated in vitro with inactivated ra- 
bies virus. Supernatants from splenocytes cultured with 
or without virus (negative control) were tested for induction 
of proliferation of the following cytokine-dependent indica- 
tor cell lines: HT-2 cells that proliferate in response to IL-2 
or IL-4, two cytokines mainly released by T helper cells 
of the Thl (IL-2) versus Th2 (IL-4) subset, CT4S cells that 
respond to IL-4 but not IL-2, 32DC13(G) cells that are 
growth dependent on I L-3 and 32DC13(G)/G M cells, a vari- 
ant line derived from the 32DC13(G) line that responds 
to IL-3 and GM-CSF (Kreider et al., 1990), two cytokines 
released by all activated T cells (reviewed by Mosmann 
and Moore, 1991). Several indicator cell lines were chosen 
to distinguish between activation of T helper cells of the 
Thl versus Th2 cell subset and to test for spontaneous 
secretion of GM-CSF by splenocytes of mice inoculated 
with the pRJB-GM vector. Although, so far, molecular de- 
tection methods such as Southern blot analysis or poly- 
merase chain reactions (Wolff et al., 1990; Ulmer et al., 
1993) or immunohistochemical analysis of protein expres- 
sion (Acsadi et al., 1991) have demonstrated vector se- 
quences or the vector-encoded antigen in muscle tissue, 
transfer of the plasmid into cells of other tissues, such as 
lymphatic organs, has not yet been formally ruled out. 
As shown in Figure 2, cytokine release by splenocytes 
in response to rabies viral antigens was strongly enhanced 
upon coimmunization with the GM-CSF-expressing vec- 
tor. Lack of an IL-4 response indicates that the DNA vac- 
cine induces mainly T helper cells of the Thl subsets, 
as was shown previously (Xiang et al., 1994), and that 
GM-CSF enhances this response pattern. IL-3 or GM-CSF 
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Figure 2. Effect of GM-CSF on the T Cell Response to the DNAVaccine 
Groups of C3H/He mice were injected with either a mixture of 50 ~g 
of pSG5 and 100 I~g of pRJB-GM (GM), 50 ~g of pSG5rab.gp and 100 
rig of pRJB-c (rab.gp), or 50 p.g of pSG5rab.gp and 100 p.g of pRJB-GM 
(rab.gp plus GM). Splenocytes were cultured 21 days later without 
addition of antigen (closed square) or with 5 p~g/ml of inactivated rabies 
virus (open square) as described (Xiang and Ertl, 1994). Supernatants 
were harvested 24 hr later and tested on HT-2, CT4S, 32DC13(G)/ 
GM (32D/G/GM), and 32DC13(G) (32DIG) indicator cells. The indicator 
cells proliferate in response to the following mouse cytokines; HT-2, 
IL-2 and IL-4; CT4S, IL-4; 32DC13(G)/GM, IL-3 and GM-CSF; 
32DC13(G), IL-3. As additional control (control), indicator cells were 
cocultured with medium (closed square) or the appropriate cytokine 
(open square), i.e., 10% rat ConA supernatant for HT-2, 2 U rlL-4 for 
CT4S, 20% WEHI supernatant for the 32DC13(G), and -/GM cell lines. 
Proliferation was measured 48-72 hr later by a 6 hr pulse with [3H]thy- 
midine. 
secretion, or both, upon restimulation with antigen was 
also increased in mice that had been inoculated with the 
pSG5rab.gp vector in combination with the pRJB-GM, vec- 
tor, some of which might reflect activation of CD8 + cytolytic 
T cells, known to be induced upon immunization with 
pSG5rab.gp. Splenocytes from mice inoculated with the 
GM-CSF-encoding vector showed no spontaneous ecre- 
tion of the cytokine in absence of the appropriate antigenic 
stimulus, indicating that any transfer of vector DNA into 
cells of the spleen that might have occurred was below 
the level of detectability by the functional assay system. 
A Plasmid Vector Expressing Mouse IFN7 Fails to 
Enhance the Immune Response to a 
Vector-Encoded Viral Protein 
IFN7 is a pleiotrophic ytokine that can improve T cell- 
mediated immune responses by up-regulating expression 
of MHC determinants (Steeg et al., 1982). To test for a local 
effect of IFNy on the efficacy of the pSG5rab.gp vector 
vaccine, groups of C3H/He mice were coimmunized with 
pSG5rab.gp and pSV2mUTII, a plasmid-encoding mouse 
IFN7 under the control of the SV40 early promoter (Grey 
and Goeddel, 1983). This immunization regiment failed to 
enhance the T cell response measured in vitro to rabies 
virus (Figure 3), but rather resulted in a slight decrease 
of cytokine release. Accordingly, the antibody response 
to rabies virus as tested by a neutralization assay (Table 
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Figure 3. Effect of IFN7 on the T Cell Response to the DNA Vaccine 
Groups of C3H/He mice were inoculated intramuscularly with either 
50 tag of pSG5rab.gp (rab.gp) or a mixture of 50 tag of pSG5rab.gp 
and 100 tag of pSV2mu711 (rab.gp lus IFN). Splenocytes were tested 
for cytokine release as described in the legend to Figure 2. 
2) or an ELISA (data not shown) was also decreased upon 
coimmunization with the IFNT-expressing plasmid. 
A Plasmid Vector Expressing Mouse GM-CSF 
Enhances the Efficacy of the DNA Vaccine 
to Rabies Virus 
The crucial test for any novel vaccination regiment is its 
effect on the morbidity/mortality upon viral challenge. The 
pSG5rab.gp vector is highly efficacious at inducing protec- 
tive immune responses; as little as 20 ~tg of plasmid given 
twice results in complete protection (Table 1). To test for 
an effect of the G M-CSF-expressing vector on the efficacy 
of the DNA vaccine to rabies virus, the dose of pSG5rab.gp 
vector was further reduced to 5 or I ixg of DNA per mouse. 
C3H/He mice inoculated with such low doses of G protein- 
expressing plasmid developed only marginal titers of VNA. 
Neutralizing antibodies protect against peripheral chal- 
lenge with rabies virus (Schumacher et al., 1989), presum- 
ably by preventing the virus from reaching the central ner- 
vous system (Shankar et al., 1991). Owing to the high 
virulence of brain-derived rabies virus, this system is 
highly sensitive, requiring only low levels of neutralizing 
antibodies to achieve complete protection against the 
small dose of infectious virus that suffices to cause a lethal 
encephalitis. All of the mice that received 5 Ixg of 
pSG5rab.gp vector with or without the pRJB-GM vector 
were fully protected against viral challenge (Figure 4). In 
mice inoculated with 1 Ixg of the rabies virus G protein- 
encoding plasmid, priming in combination with the pRJB- 
GM plasmid improved the efficacy of the DNA vaccine; 
while only 40% of the mice inoculated with 1 p.g of 
pSG5rab.gp survived the challenge with rabies virus, 80% 
of mice inoculated with the same dose of the antigen- 
expressing vector in combination with the GM-CSF- 
expressing vector remained symptomless after infection. 
Discussion 
Our data show that coimmunization of mice with a plasmid 
expressing a viral antigen, i.e., the G protein of rabies 
virus, with a plasmid expressing mouse GM-CSF in- 
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Figure 4. Effect of GM-CSF on the Efficacy of the DNA Vaccine 
Groups of mice were inoculated with 100 tag of pRJB-GM or 100 p.g 
of pRJB-c and 5 or 1 ixg of pSG5rab.gp. Mice were boosted 3 weeks 
later with the same amount of pSG5rab.gp used for the initial inocula- 
tion. Mice were bled 2 weeks later and VNA titers were determined. 
Mice were challenged the same day with 10 LDs0 of CVS-24 virus 
given intramuscularly and survival was assessed. Open square, 5 tag 
of pSG5rab.gp lus 100 tag of pRJB-GM; VNA titer: 1:45; closed dia- 
mond, 5 I.tg of pSG5rab.gp lus 100 ~g of pRJB-c; VNA titer: 1:10; 
open diamond, 1 Ixg of pSG5rab.gp lus 100 ~g of pRJB-GM; VNA 
titer: 1:5; closed square, 1 Ixg of pSG5rab.gp lus 100 I.tg of pRJB-c; 
VNA titer: 1:5. 
creases the antiviral immune response, while coinjection 
with a vector expressing mouse IFN7 has no such effect. 
It has been shown previously in several viral systems, 
including ours, that intramuscular inoculation of plasmid 
vectors carrying a viral gene under the control of an appro- 
priate promoter esults in stimulation of a specific immune 
response to the vector-encoded antigen (UImer et al., 
1993; Xiang et al., 1994). Plasmid vectors carrying reporter 
genes helped to identify striated muscle cells as the only 
cell type serving in situ as efficient argets for intramuscu- 
lar transfection (Wolff et al., 1990). Within skeletal muscle 
cells, vector DNA was found to persist without replication 
or incorporation into the host cell genome for several 
months (Wolff et al., 1990, 1992). Pretreatment with drugs 
causing muscle degeneration followed by regeneration 
was shown further to increase uptake of plasmid DNA into 
muscle cells, leading to an improved immune response 
(Wang et al., 1993). Myoblasts and myocytes express only 
low levels of MHC class I determinants and fail to express 
MHC class II molecules (reviewed by Hohlfeld and Engel, 
1994). Treatment of myoblast cultures with IFNy was 
shown in vitro to cause up-regulation of MHC class I mole- 
cules, and to induce the expression of MHC class II deter- 
minants, in consequence rendering myoblasts usceptible 
to T cell-mediated cytolysis and, furthermore, enabling 
them to provide stimulatory signals to proliferative T cell 
lines. These studies, showing the cytokine-induced ability 
of muscle cells to serve as targets for T cell recognition, 
were taken as evidence for the capacity of in situ 
transfected myocytes/myotubes to stimulate the primary 
immune response observed after DNA immunization. Ex- 
pression of foreign proteins exclusively by muscle cells is 
not expected to result in the stimulation of a primary im- 
mune response. To initiate activation of virgin T cells, pre- 
Immune Responses to a DNA Vaccine 
133 
sentation of foreign determinants by professional APCs, 
i.e., dendritic cells that, in addition to MHC class I and II 
determinants, express costimulatory molecules such as 
B7 (Bretscher, 1992; June et al., 1994; Linsley et al., 1991) 
is required. DNA vaccination clearly causes stimulation 
of a primary immune response, suggesting that not only 
muscle cells but also resident APCs such as Langerhans' 
dendritic cells present the transantigen, i.e., the vector- 
encoded foreign protein. Data shown in this study support 
this assumption; inoculation of a mixture of an antigen- 
presenting vector with a plasmid encoding GM-CSF, a 
cytokine known to enhance the antigen-presenting capac- 
ity of dendritic cells, clearly improves the T helper and B 
cell response to a DNA vaccine. Although expression of 
transantigen has been demonstrated histologically in mus- 
cle fibers, it has not been demonstrated in APCs such as 
dendritic ells, potentially reflecting the inadequate sensi- 
tivity of the experimental pproach in detecting the prover- 
bial needle in the haystack, i.e., the small number of APCs 
within the muscle tissue. Alternatively, antigen released 
by transfected muscle cells might be reprocessed and pre- 
sented by APCs either activated or recruited, owing to the 
local effect of GM-CSF. The rabies virus G protein is firmly 
anchored in the cell membrane by a transmembrane do- 
main, and in vitro studies using fibroblasts expressing the 
G protein upon transfection with the pSG5rab.gp vector 
failed to demonstrate sufficient amounts of the protein in 
the culture supernatants of the transfected cells to trigger 
proliferation of a G protein-specific T cell line (Xiang and 
Ertl, 1994) that otherwise responds to nanomolar concen- 
trations of peptide antigen (Otvos et al., 1995, submitted). 
By the same token, the influenza A virus nucleoprotein 
that lacks a signal sequence and is thus cytoplasmatically 
retained rather than secreted induces an immune re- 
sponse, including cytolytic T cells upon expression by a 
plasmid vector vaccine (Wang et al., 1993). Muscle fibers 
damaged due to the inoculation ofthe plasmid might result 
in the release of viral protein, but previous studies have 
indicated that injured cells fail to take up and express plas- 
mid DNA (Wolff et al., 1992). In either case, reprocessing 
of the muscle cell-derived transantigen by professional 
APCs might induce MHC class II-restricted T cells but is 
not expected to activate efficiently cytolytic T cells that as 
a rule recognize MHC class I-associated peptides derived 
by cytosolic degradation of de novo synthesized foreign 
proteins (reviewed by Germain, 1994). We thus currently 
favor the explanation that inoculation of vector DNA 
causes direct ransfection of APCs, and that the enhancing 
effect of coimmunization with the GM-CSF-expressing 
vector on the immune response to the vector-encoded viral 
antigen reflects activation or recruitment of APCs to the 
site of inoculation enhancing primarily the Thl cell re- 
sponse to the rabies virus G protein, in consequence lead- 
ing to an enhanced B cell response most notable after 
booster immunizations. The increase in the B cell re- 
sponse, in turn, improves the vaccine efficacy, which in the 
case of a peripheral infection with rabies virus is correlated 
with neutralizing antibody titers. 
While coinoculation of the pSG5rab.gp vector with the 
GM-CSF-expressing vector reproducibly enhanced the 
immune response to the viral antigen, coinoculation with 
an IFNy-expressing plasmid that in vitro resulted in sub- 
stantial secretion of cytokine upon transient ransfection 
of fibroblasts (data not shown) failed to affect positively 
the stimulation of B or T helper cells to the vector-encoded 
viral antigen. This indicates that the anticipated increase in 
expression of M HC determinants at the site of transfection 
fails to enhance the induction of the immune response 
upon DNA vaccination. The slight decrease in the T helper 
and B cell response might reflect a negative effect of IFNy 
on stimulation or proliferation of T cells. Alternatively, up- 
regulation of MHC determinants might result in a more 
efficient clearance of transantigen-expressing muscle 
cells, which might consequently limit the immune re- 
sponse. One of the most intriguing aspects of DNA vacci- 
nation is the long-lasting expression of the vector-encoded 
proteins in muscle cells in spite of an ongoing immune 
response. The antigenic persistence might indicate that 
the majority of the antigen-expressing cells is being ig- 
nored by the immune effector mechanisms, which might 
be a reflection of the low levels of MHC class I determinant 
on muscle cells. Normal turnover of muscle cells, minor 
leakage of antigen, or the occasional encounter between 
antigen-MHC complexes on muscle cells and already in- 
duced T cells might suffice to maintain an immune response 
for prolonged periods of time. Concomitant inoculation of 
an IFNy-expressing vector with an antigen-expressing 
vector might lead to up-regulation of MHC determinants 
and, in consequence, to improved recognition by T effector 
cells, resulting in rapid elimination of antigen-expressing 
muscle cells followed by termination of the immune re- 
sponse, a hypothesis that is currently being tested by our 
group. 
Regardless of the mechanisms involved in inducing and 
maintaining the immune response, plasmid vectors might 
open new avenues not only for gene therapy or as vaccines 
to infectious agents, but also for treatment of cancers that 
carry well-defined immunogenic determinants. Using the 
approach described in this study, i.e., inoculating mixtures 
of antigen-expressing plasmids with cytokine-encoding 
plasmids, or, alternatively, using poiycistronic vectors ex- 
pressing both within one construct might improve the effi- 
cacy of DNA vaccines. It might also provide a technically 
undemanding tool to gain further insight into the local inter- 
play between antigen and cytokines needed for the initia- 
tion of immune responses. 
Experimental Procedures 
Animals 
Female C3H/He mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine). Time-pregnant outbred ICR mice and female Lewis 
rats were purchased from Harlan Sprague-Dawley (Indianapolis, Indi- 
ana). Mice were maintained atthe Animal Facility of The Wistar Insti- 
tute and used between 8-12 weeks of age. Rats were used at the age 
of 3-4 months. 
Cells 
Baby hamster kidney (BHK)-21 cells and Walter and Eliza Hall Institute 
(WEHI) cells were maintained inDulbecco's minimal essential medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS) and antibi- 
otics. The HT-2 indicator cell line was grown in DMEM containing 10% 
FBS, 10 6 M 2-mercaptoethanol (2-ME), and 10% rat concanavalin A 
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(ConA) supernatant as a source of growth factors. The CT4S indicator 
cell line (provided by Dr. W. Paul, National Institutes of Health/National 
Instititute of Allergy and Infectious Diseases, Bethesda, Maryland) was 
cultured in HEPES buffer-free DMEM, 10% FBS, 10 -6 M 2-ME, and 
10 U/ml of recombinant IL-4. The 32DC13(G) and 32DC13(G)/GM cell 
lines (provided by Dr. G. Rovera, The Wistar Institute, Philadelphia, 
Pennsylvania) were grown in DMEM, 10% FBS, and 30o/o WEHI cell 
conditioned medium. 
Viruses 
Rabies virus of the ERA strain was propagated on BHK-21 cells, puri- 
fied, and inactivated with betapropionolactone (BPL) as described pre- 
viously (Wiktor, 1973). The CVS-24 strain of rabies virus, which is 
antigenically closely related to the ERA strain but shows higher viru- 
lence in mice, was derived from brain suspensions of infected newborn 
ICR mice (Wiktor et al., 1977). 
Lymphokines 
Recombinant mouse IL-4 was obtained from Collaborative Biomedical 
Products (Bedford, Massachusetts). Rat ConA supernatant was gener- 
ated from 48 hr culture supernatant of ConA (2.5 pg/ml)-treated Lewis 
rat splenocytes as described. WEHI-conditioned medium was derived 
from cell-free 48 hr supernatant of confluent WEHI cell cultures. 
Expression Vectors 
The pSG5 vector was obtained from Stratagene, Incorporated (La 
Jolla, California). The pSG5rab.gp vector had been constructed by 
insertion of the full-length cDNA encoding the rabies virus G protein 
gene into the unique Bglll site of the multicloning site of the pSG5 
vector under the control of the SV40 early promoter (Burger et al., 
1991). Appropriate expression of the G protein was confirmed upon 
stable transfection of mouse fibroblasts (Xiang and Ertl, 1994). The 
pRJB-GM vector had been designed to express mouse GM-CSF under 
the control of the Rous long-terminal repeat and nee controlled by the 
SV40 early promoter (Altmann et al., 1991). Appropriate expression 
of mouse GM-CSF was confirmed upon stable transfection of BHK-21 
cells using the 32DC13(G)/GM indicator cell line (data not shown). A 
control vector, termed pRJB-c, was generated by excising the GM-CSF 
gene by digestion with Xbal and Hindlll, followed by a fill-in reaction 
and blunt end ligation of the agarose-purified vector fragment. The 
pSV2mu~,ll vector (Grey and Goeddel, 1983), expressing mouse IFN~f 
under the control of the SV40 early promoter (confirmed by testing 
supernatants from pSV2muTII-transfected BHK cells for reduction of 
encephalo-myocarditis virus-induced plaque formation on mouse fi- 
broblast monolayers; data not shown), was provided by Genentech, 
Incorporated (San Francisco, California). 
Plasmid vectors were grown in transformed Escherichia coil bacte- 
ria, strain DH5a in LB broth supplemented with ampicillin. Large scale 
purification was conducted using the Promega Magic Maxiprep Purifi- 
cation System according to the protocol of the manufacturer. The con- 
centration of the purified plasmid vectors was determined by agarose 
gel electrophoresis against a standard marker. 
Immunization and Infection of Mice 
Groups of C3H/He mice were injected intramuscularly into the left 
quadriceps with plasmids diluted in 100-150 p.I of saline or with 5 pg/ 
mouse of ERA-BPL virus also diluted in saline. In some experiments, 
mice were boosted 2-3 weeks later by an additional dose of plasmid 
or viral antigen given intramuscularly. Mice were challenged with 10 
LD~0 of CVS-24 virus given intramuscularly; they were observed for 
the following 3 weeks for symptoms indicative of a rabies virus infec- 
tion. Mice that developed complete bilateral hindleg paralysis (pro- 
ceeding death by 24-48 hr) were euthanized for humanitarian reasons. 
Antibody Assays 
Blood samples were obtained by retro-orbital puncture. Sera were 
prepared, heat-inactivated, batched, and stored at -20°C. 
Neutralization Assay 
VNA titers were determined on BHK-21 cells using infectious ERA 
virus at 1 plaque-forming unit per cell (Ertl et al., 1990). Data are 
expressed as neutralization titers that are the reciprocal of the serum 
dilution resulting in a 50% reduction in the number of infected cells. 
Samples were assayed in duplicate in serial 3-fold dilutions starting 
with a dilution of 1:5 or 1:15. Standard deviations were within 10% 
for any given experiment. 
ELISA 
The ELISAs were conducted in 96-well microtiter plates coated with 0.2 
lig/well of ERA-BPL virus using an alkaline phosphatase-conjugated 
goat anti-mouse immunoglobulin as second antibody, as described in 
detail previously (Xiang and Ertl, 1992). 
Lymphokine Release Assays 
Splenocytes from immunized mice (4 × 106/well) were cultured in 1.6 
ml of DMEM supplemented with 10 6 2-ME and 2% FBS in 24-well 
Costar plates without antigen (control) or with 5 lig/ml of ERA-BPL 
virus. Cell-free supernatants were harvested 24 hr later. Secretion of 
IL-2, IL-4, or both, was tested on HT-2 cells; IL-4 activity was measured 
on CT4S cells; IL-3 and GM-CSF secretion was assessed on 
32DC13(G)/GM cells; and IL-3 (without GM-CSF) release was deter- 
mined on 32DC13(G) cells. For each of these different cell lines, 2 x 
103 cells in 100 p.I of the appropriate culture medium were cocultured 
with 50 i~1 of supernatants from lymphocyte cultures. Medium was 
used as a negative control, cytokines (rlL-4, 10 U/ml for CT4S ceils, 
10% rat ConA supernatant for HT-2 cells, or 30% WEHI cell superna- 
tant for 32DC13(G) and 32DC13(G)/GM cells) were used as positive 
controls. Proliferation of the indicator cells was tested 48-72 hr later 
by a 6-6 hr pulse with 0.35 liCi of [3H]thymidine. 
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